Skip to content

Trial Summary

A Study of CS5001 in Patients With Advanced Solid Tumors and Lymphomas

Acronym:

CS5001-101

ACTRN/NCT /ethics:

NCT05279300

Scientific title:

A Phase I, Dose-Escalation and Dose-Expansion Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Antitumor Activities of CS5001, an Anti-ROR1 Antibody Drug Conjugate, in Patients with Advanced Solid Tumors and Lymphomas

Sponsor / Cooperative group:

Cstone

Trial & Patient Characteristics

Cancer TypeAll cancers; Lymphoma
Trial TypeTreatment
PhasePhase I
Age Range18 years and older
SexAll
Tumour Stream -
Cancer StageLocally Recurrent or Locally Advanced
Anticipated Start Date2022-04-01
Anticipated End Date2024-03-31

Participating Hospitals

HospitalIcon Cancer Centre Adelaide
Clinical Trial CoordinatorSue Yeend
Emailsue.yeend@icon.team
Phone08 8292 2204
Principal InvestigatorDr Sarwan Bishnoi
Recruitment StatusNot Yet Recruiting